Interview with Mal Eutick, CEO, Phebra Australia
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Address: 332 Burns Bay Road, Lane Cove, NSW 2066, Australia
Tel: +61 (0) 2 9420 9199
Web: http://www.phebra.com.au/
Phebra specialises in the development, manufacture, marketing and distribution of highly specialised and innovative medicines for the hospital market.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of pharmaceuticals in important disease areas such as anti-infectives, antidotes, diagnostic dyes and agents, oncology, pain and other specialty pharmaceuticals.
Our products are distributed in Australia, New Zealand, Asia, Canada and Europe.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of products in the following therapeutic areas:
anti-infectives
antidotes
cardiovascular and respiratory disease
central nervous system
diagnostic dyes and agents
infusion solutions, intravenous additives and electrolyte replacement solutions
oncology and pain
vitamins
specialty pharmaceuticals
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the…
The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
Australia, the “land down under” to many Westerners, is sometimes left at just that — out of sight, and out of mind. But investors who ignore Australia do so…
See our Cookie Privacy Policy Here
